Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study

By sjmartinez • September 11, 2024

Chalmers JD, Shteinberg M, Mall MA, O'Donnell AE, Watz H, Gupta A, Frahm E, Eleftheraki A, Rauch J, Chotirmall SH, Armstrong AW, Eickholz P, Hasegawa N, Sauter W, McShane PJ. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study. Eur Respir J. 2024 Sep 10:2401551. doi: 10.1183/13993003.01551-2024. Epub ahead of print. PMID: 39255990.

Tags: Dermatology, Publications

MicroBayesAge: a maximum likelihood approach to predict epigenetic age using microarray data

Nolan N, Mitchell M, Mboning L, Bouchard LS, Pellegrini M. MicroBayesAge: a maximum likelihood approach to predict epigenetic age using microarray data. Geroscience. 2025 May[...]

Characterization of IgE cross-reactivity and allergenicity of peanut allergens

Lapitan C, Zhang WR, Guo B, Daniels-Wells TR, Penichet ML, Zhang K. Characterization of IgE cross-reactivity and allergenicity of peanut allergens. Immunohorizons. 2025 May 30;9(7):vlaf018.[...]

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

Merola JF, Mease PJ, Armstrong AW, Strand V, Lehman T, Varga S, Choi JC, Becker B, Zhong Y, Colombo MJ, Thaçi D, Bili A, Gottlieb[...]